Lineage Cell Therapeutics Announces RG6501 Phase 1/2A Additional Results to Be Featured At 23rd EURETINA Congress
Portfolio Pulse from Benzinga Newsdesk
Lineage Cell Therapeutics announced that additional results from the RG6501 Phase 1/2A trial will be presented at the 23rd EURETINA Congress in Amsterdam, October 5-8, 2023. The presentation will be given by Adiel Barak, M.D., on behalf of Roche and Genentech.
September 13, 2023 | 12:19 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Lineage Cell Therapeutics' RG6501 Phase 1/2A trial results will be presented at a major conference, potentially increasing visibility and interest in the company.
The presentation of trial results at a major conference often leads to increased visibility and interest in the company, which can positively impact the stock price in the short term.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100